Detail akcie Santhera Pharm H Rg online

Business Summary: Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company operates through one business segment, which is the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases, such as Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF). The Company focuses also on development of gene therapy for the treatment of LAMA2 (Laminin Subunit Alpha 2) deficient congenital muscular dystrophy (CMD). Santhera operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Santhera Pharmaceuticals Holding AG revenues decreased 62% to SF39.1M. Net loss totaled SF42M vs. income of SF54.8M. Revenues reflect North America segment decrease of 88% to SF11.4M. Net loss reflects Development and commercialization of products for the treatm segment loss totaling SF33.1M vs. income of SF68.8M.